In a report released today, Michael Matson from Needham reiterated a Buy rating on Hologic (HOLX), with a price target of $52. The company’s shares closed yesterday at $49.21, close to its 52-week high of $49.78.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 10.3% and a 67.3% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Cardiovascular Systems, and Zimmer Biomet Holdings.
Hologic has an analyst consensus of Moderate Buy, with a price target consensus of $49.40.
See today’s analyst top recommended stocks >>
Based on Hologic’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $273 million. In comparison, last year the company had a GAAP net loss of $681 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following business segments: Breast Health, Diagnostics, Medical Aesthetics, GYN Surgical, and Skeletal Health.
